VISIONARY Study Group Selected Research

tafluprost

8/2022	Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
1/2022	A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy.
1/2022	Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
1/2020	Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
1/2020	Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

VISIONARY Study Group Research Topics

Disease

5	Open-Angle Glaucoma (Glaucoma, Open Angle) 08/2022 - 01/2020
5	Ocular Hypertension (Glaucoma, Suspect) 08/2022 - 01/2020
1	Hyperemia 01/2022
1	Foreign Bodies (Foreign Body) 01/2020
1	Dry Eye Syndromes (Dry Eye Syndrome) 01/2020
1	Pruritus (Itching) 01/2020

Drug/Important Bio-Agent (IBA)

5	Timolol (Blocadren)FDA LinkGeneric 08/2022 - 01/2020
5	tafluprostIBA 08/2022 - 01/2020
3	Prostaglandins AIBA 01/2022 - 01/2020
3	Synthetic Prostaglandins (Prostaglandin Analogues)IBA 01/2022 - 01/2020
2	Fluorescein (Funduscein)FDA LinkGeneric 01/2022 - 01/2020
1	Latanoprost (Xalatan)FDA Link 01/2022
1	Bimatoprost (Lumigan)FDA Link 01/2022

Therapy/Procedure

2	Therapeutics 01/2020 - 01/2020